Novo Nordisk A/S (NVO) : Analyst Rating Update

Novo Nordisk A/S (NVO) : Zacks Investment Research ranks Novo Nordisk A/S (NVO) as 4, which is a Sell recommendation. 1 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 3 research analysts is 2.33, which indicates as a Buy.

Novo Nordisk A/S (NYSE:NVO): The stock opened at $53.22 on Wednesday but the bulls could not build on the opening and the stock topped out at $53.87 for the day. The stock traded down to $52.91 during the day, due to lack of any buying support eventually closed down at $53.82 with a loss of -0.76% for the day. The stock had closed at $54.23 on the previous day. The total traded volume was 1,106,289 shares.

The company shares have rallied 1.08% from its 1 Year high price. On Aug 3, 2015, the shares registered one year high at $60.34 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $54.18 and the 200 Day Moving Average price is recorded at $54.44.

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio, including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and biopharmaceuticals. The Companys diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. Its biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. The primary production facilities owned by the Company are located at a number of sites in Denmark, and internationally in the United States, France, China and Brazil.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.